Martin Babler is our Chief Executive Officer, President and Chairman of our Board since September 2021. Prior to joining Alumis, he served as President and Chief Executive Officer of Principia Biopharma, until its acquisition by Sanofi S.A. in October 2020. Prior to joining Principia Biopharma, Martin served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. From 1998 to 2007, he held several positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. While at Genentech, he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Martin previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. He presently serves on the Board of Directors of Neoleukin Therapeutics, Inc., Prelude Therapeutics Inc., Omega Alpha SPAC, Sardona Therapeutics and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Martin received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.

Sara Klein is our General Counsel and Secretary. Before joining Alumis, she was Head of Legal at Principia Biopharma following that company’s acquisition by Sanofi, and Senior Vice President, Legal prior to the acquisition. At Principia Sara had general responsibility for the company’s legal, IP and compliance functions, and co-chaired the Operating Committee and the COVID-19 Response Committee. Prior to joining Principia, Sara was in the private practice of law representing life science and technology companies. She started her career at the law firm of Baker & McKenzie, followed by five years as an in-house lawyer at Genentech. Sara graduated from Middlebury College and U.C. Hastings College of the Law.

Roy Hardiman is our Chief Business Officer and general counsel, with over 30 years of business development, legal, alliance management and strategic experience in the biopharmaceutical field. Prior to joining Alumis, he was Chief Business Officer of Principia Biopharma where he negotiated Principia’s core collaborations with Sanofi and AbbVie. Roy spent almost two decades at Genentech where he was one of Genentech’s lead negotiators, with personal accountability for the legal and alliance aspects of Genentech’s relationship with Roche. Roy’s roles at Genentech included vice president of alliance management, vice president of corporate law, and director and Far East representative for business development. Prior to joining Genentech, Roy was an attorney with Morrison-Foerster. Roy received his BA in pharmacology and MA in biology (biochemistry/molecular biology emphasis) from University of California, Santa Barbara, and his JD from University of California, Los Angeles School of Law, and serves on the Board of Trustees of the University of California, Santa Barbara Foundation.

John R. Schroer joins Alumis from ArsenalBio where he served as chief financial officer. Prior to that role, Mr. Schroer served as chief financial officer and treasurer at Translate Bio. From January 2014 to April 2018, Mr. Schroer served as a director and sector head – healthcare at Allianz Global Investors, a global asset management company. From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded. Mr. Schroer received a B.S. in history and international relations and an MBA from the University of Wisconsin-Madison.

Mark Bradley is the chief development officer of Alumis, bringing more than 25 years of experience in the biotechnology industry. Mark joins Alumis from Bristol Myers Squibb (BMS) where he has served as senior vice president & site head since BMS’s acquisition of MyoKardia, a precision medicine company focused on treating cardiovascular diseases. Prior to that, he held roles of increasing responsibility at MyoKardia, most recently as senior vice president, development. Before MyoKardia, Mark held roles of increasing responsibility at Genentech from 2004-2017, most recently serving as head, business management gRED clinical operations. Mark began his career at UCSF in public health research.

David M Goldstein, Ph.D. is our Chief Scientific Officer and is a recognized expert in the fields of small molecule drug discovery, kinase inhibitor design and covalent technologies. David has greater than 25 years of industrial experience and has led teams that advanced many small molecule drug candidates into clinical trials in autoimmune diseases and oncology including tolebrutinib, rilzabrutinib and pamapimod. He is a named inventor on more than 40 patents and he has authored more than 40 scientific publications. Most recently, David was the Chief Scientific Officer at Principia Biopharma, a company he helped to launch in 2011 and take public in 2018. Prior to joining Principia, David held positions of increasing responsibility at Roche including Senior Director, Medicinal Chemistry and Head of Inflammation Chemistry. David is currently a Board member of Frontier Medicines in South San Francisco. David received his Ph.D. in Chemistry at the University of Virginia and completed postdoctoral studies in organic chemistry at the University of Pittsburgh.

Claire is a recognized leader in the field of immunology, with a focus on drug discovery in immune mediated diseases. Claire previously served as Vice President, Head of Immunology and Biology at Principia, where she championed target biology, preclinical and clinical translation, building novel insights and deeper understanding of BTK beyond the B cell. Prior to Principia, she held positions of increasing responsibility at DNAX, Roche, Takeda and Theravance. During her postdoctoral studies, Claire was credited with the discovery of Th17 cells, and uncovered the key role of IL-23 and IL-17 in autoimmunity, prompting rewritten text-books and a new wave of approved medicines for patients. Claire received a B.Sc. in Biochemistry from Imperial College London, and a Ph.D. in Immunology from Great Ormond Street Institute of Child Health, University College London, UK.

Dr. Drappa is a board certified rheumatologist with over 25 years experience in developing novel treatments for autoimmune and inflammatory diseases. Most recently, he served as chief medical officer at Ventyx Biosciences.

Prior to Ventyx, Dr. Drappa co-founded Viela Bio, a biotechnology company focused on the discovery, development and commercialization of treatments for autoimmune and severe inflammatory diseases and served as its Head of R&D and Chief Medical Officer through its acquisition by Horizon Therapeutics in March 2021. At Viela Bio, Dr. Drappa led the development of UPLIZNA™ (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

Prior to Viela Bio, he held various roles of increasing responsibility leading clinical development programs at MedImmune/AstraZeneca, Genentech/Roche, and Amgen. Dr. Drappa received his medical and Ph.D. degrees from the University of Cologne in Germany. He completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in rheumatology at the Hospital for Special Surgery, NY.

David Zhang, Ph.D., is our senior vice president and chief information officer. Before joining Alumis, he was vice president of biometrics, data science and digital health at Bristol Myers Squibb following the company’s acquisition of MyoKardia. At MyoKardia, David built the advanced analytics capabilities from ground up to enable the successful completion of critical data readouts and New Drug Application submission. David has over two decades of industry experience spanning from biopharma to diagnostics product development. Prior to MyoKardia, David spent 15 years at Roche/Genentech with increasing responsibilities leading and building biostatistics and strategic innovation functions. David began his pharmaceutical industry career at Eli Lilly and Abbott Laboratories. He received his Ph.D. in biostatistics with a minor in genetics from UCLA School of Public Health and completed post-doctoral research at Columbia University.

Dr. Rubio comes to Alumis from Revance, where he was Senior Vice President of Clinical Development overseeing Phase 1, 2 and pivotal Phase 3 programs in both dermatology and neurology. Prior to Revance, Dr. Rubio served more than 11 years at Genentech, Inc., ascending through a number of clinical and development management roles to Global Head of Ophthalmology.  While at Genentech, he held key leadership roles in the successful development and approval of several ophthalmic indications for Genentech’s Lucentis* (ranibizumab injection).

Dr. Rubio has an MBA in Health Care Management and Finance from The Wharton School, University of Pennsylvania, and received his Doctor of Medicine from University of California, San Francisco. He completed a Master of Science, Health and Medical Sciences from the University of California, Berkeley, and has a Bachelor of Science, Biological Sciences from the University of Notre Dame.

Jeff Douglas is vice president of clinical operations at Alumis and brings more than 25 years of clinical research and development experience. Jeff joins Alumis from MyoKardia, where he served as head of clinical operations. Most recently, he successfully led the global development operations transition and integration with Bristol Myers Squibb. Prior to his tenure at MyoKardia, Jeff was the program director of Genentech’s research and development clinical operations where he oversaw programs focused on cancer immunotherapy and hematologic malignancies and helped to lead more than 30 compounds through preclinical development into late stage development. Jeff began his career as a practicing pharmacist after graduating with a Doctor of Pharmacy degree from the University of Missouri, Kansas City.

Ken Brameld, Ph.D., is our Fellow, Head of Research. Before joining Alumis, he was senior vice president and Head of Research at Principia Biopharma. At Principia Biopharma, Ken was instrumental in launching the company in 2011 and helped build the Tailored Covalency platform central to the company’s success. During his tenure, the small molecule drug discovery team discovered and progressed four molecules into clinical development, including rilzabrutinib and tolebrutinib. Prior to Principia Biopharma, Ken spent four years at Roche Palo Alto, where he was a Principal Scientist and the Computational Chemistry group leader until the site closure in 2010. Ken began his biotech career with positions of increasing responsibility at Scios, Array Biopharma, and Celera. He earned his Ph.D. in Chemistry from Caltech under the supervision of Prof. William Goddard, III and went on to a postdoctoral fellowship at UCSF in the laboratory of Prof. Irwin “Tack” Kuntz.

Tori Lovell is our HR business partner. She brings over 6 years of experience in office management and Human Resources to her role. Prior to joining Alumis, Tori was at Principia Biopharma where she held many different roles with increasing responsibility in HR, facilities management and office management, most recently as HR Generalist. During this time, Tori’s main focus was supporting the company’s hiring, growth and ensuring an exceptional employee experience. Her areas of specialty include employee experience, onboarding, employee benefits, and compensation. Tori received her bachelor’s degree in Business Administration with a focus in Human Resources from Brandman University. Outside of work, Tori enjoys sports and spending her free time with family and friends.

Mike Taylor is our Vice President of Toxicology. Mike has over 30 years in the pharmaceutical industry beginning with Syntex Research in Palo Alto, CA. Most recently, he was the Founder and Principal of NonClinical Safety Assessment, a consulting firm focusing on the safety evaluation of drugs and medical devices. Mike’s experience spans a variety of therapeutic areas, successfully supporting the development of both novel and repurposed therapeutics. He has held executive leadership positions at Roche Bioscience, Durect Corporation, Protein Design Labs, Alexza Pharmaceuticals, and Limerick BioPharma. Mike is currently a mentor in Stanford University’s SPARK program, providing pharmaceutical development guidance to students and aspiring entrepreneurs. He holds Ph.D. and M.S. degrees in toxicology from Utah State University with postdoctoral training at the CNRS of France and the NIH, is a member of the Society of Toxicology and the American College of Toxicology and is certified by the American Board of Toxicology. Mike is author/co-author of more than 50 publications, including peer-reviewed articles, book chapters, and abstracts.

David has more than 10 years of experience in small molecule drug development ranging from the pre-clinical stage to process validation.  Prior to joining Alumis, David was the head of the formulation development and manufacturing group at Myovant Sciences where he led the late-stage drug product development and validation efforts for both Myfembree and Orgovyx.  Before joining Myovant, David was a research scientist in the formulation and process development group at Gilead Sciences where he served as the lead formulator on several projects.  David began his industrial career working in the pharmaceutics group at Abbott Laboratories.  David received his Ph.D. in Industrial and Physical Pharmacy from Purdue University under the guidance of Professor Lynne S. Taylor in 2010.

Carmen Munoz supports Alumis as Sr. Administrative Assistant / Project Coordinator. Prior to Alumis, she spent 8 years as Sr. Administrative Associate at Genentech, supporting a group of 100+ global employees, from executives to individual contributors. During her time at the Oncology Biomarker Department in gRED, Carmen was involved in running multiple special projects and events.  Carmen is currently seeking her Bachelor’s Degree in Accounting. Outside of work, Carmen enjoys spending time with her family and friends.

Shereen McIntyre is Executive Director, Data Management at Alumis and brings more than 22 years of pharmaceutical and biotechnology industry experience. Prior to joining Alumis, Shereen was Executive Director of Data Management at Bristol Myers Squibb, where she led integration and transition activities for her function following the company’s acquisition of MyoKardia. At MyoKardia, Shereen built and lead the data management function, inclusive of clinical programming, ensuring successful completion of key data deliverables in support of the company’s New Drug Application filing. Before MyoKardia, Shereen also served as head of data management at Avanir Pharmaceuticals and Five Prime Therapeutics, respectively. Shereen started her career at Amylin Pharmaceuticals in San Diego, where she held biometrics positions of increasing responsibility over her 15-year tenure at the company. Throughout her career, she has supported multiple regulatory drug filings and has helped bring multiple drugs to approval. Shereen holds a MBA in Management from San Diego State University and a Bachelor of Science in Biochemistry and Cell Biology from UC San Diego.

Milly Kitty Toor is senior director, commercial development, at Alumis. Milly joined Alumis from Bristol Myers Squibb / Myokardia, where she served as director, HCP marketing leading brand strategy and market development for mavacamten’s launch. Prior to joining MyoKardia, Milly held roles of increasing responsibility at Gilead and ZS Associates for over 10 years with focus on go to market and portfolio strategy. Milly has global healthcare experience as she worked extensively in Europe and did her MBA at HHL (Leipzig Graduate School of Management).

Regan Burns is Associate Director of clinical operations at Alumis and brings more than 10 years of clinical research and development experience.  Regan joins Alumis from CymaBay where she oversaw a suite of clinical pharmacology studies. She was previously a Sr Clinical Trial Manager at Principia Biopharma running the hematology rare disease Phase 2 and 3 studies.  Her career has mainly focused on autoimmune disease research from immune thrombocytopenia to biosimilar research in psoriasis and rheumatoid arthritis.  Regan began her career as a pharmacy technician and has a Bachelor’s degree from University of California, Santa Barbara.

Derrick Richardson is our Vice President of Program Management and brings over 25 years of experience spanning drug and medical device development. Derrick joins Alumis from Bristol Myers Squibb where he served as the Head of Cardiovascular Project Management overseeing the late-stage execution of a therapeutic area portfolio focused on thrombosis and cardiomyopathies including Mavacamten and Eliquis. Prior to the acquisition, Derrick served as Executive Director, Project Management at MyoKardia where he grew and developed a PMO that integrated rapidly evolving research, clinical development, BD and commercial functions. He has also worked as a consultant to AbbVie and Genentech, providing Project Management, Business Operations and BD leadership across multiple therapeutic areas including oncology, multiple sclerosis and ocular disease. Earlier in his career, Derrick worked as a Mechanical Engineer at Stryker Corporation and Johnson & Johnson contributing to several innovations in laparoscopic surgery, lab automation and cardiovascular implants. He holds a BS in Product Design Engineering from Stanford University and a Master of Engineering in Mechanical Engineering from Cornell University.

Fareha Iqbal, M.D. is an Associate Medical Director of clinical development at Alumis. Fareha joins from Biosplice Therapeutics where she was working as an Associate Medical Director. Prior to joining Biosplice, Fareha was working as an Associate Clinical Research Director at Principia, a Sanofi company, on phase II and III studies. Fareha started her biotech career at Principia on the operations side. Before that she worked as a Research Associate at UCSF for a couple of years. Fareha holds a M.B.B.S degree from Pakistan, where she worked as a primary care physician for many years.

Dennis Leventis is the Associate Director of IT at Alumis and brings over 20 years of IT experience.  He joins Alumis from Actelion, a J&J Company where he was the IT Services Manager and IT Infrastructure Team Lead and oversaw the Americas Global Service Desk team. Most recently, Dennis served as Senior Manager of Business Applications and Customer Support at Principia Biopharma. In this role, he oversaw all aspects of IT operations, including infrastructure support, incident management, and customer service. He also collaborated closely across various business units to plan and deploy applications in alignment with corporate leadership.  Dennis received his bachelor’s degree in Computer Science from San Francisco State University. Outside of work, he loves to travel and spend time with family and friends.

Kolbot By joins Alumis as Senior Vice President of Technical Operations.  He has more than 20 years of experience in the biopharmaceutical industry, overseeing manufacturing processes of new chemical entities, and advancing development programs from proof of concept to commercial production.  Prior to Alumis, Kolbot was Senior Vice President, Technical Operations at Rain Therapeutics where he led the late-stage CMC development program.   Prior to Rain Therapeutics, Kolbot was Vice President, Chemical Development at Principia Biopharma (acquired by Sanofi), where he led the late-stage drug substance program.  Prior to Principia he was at Corvus Pharmaceuticals, Onyx Pharmaceuticals (acquired by Amgen), Aryx Therapeutics, and NPS Pharmaceuticals.  While at Onyx, Kolbot helped to develop the carfilzomib drug substance program from phase 2 through commercialization.  Kolbot holds a B.S. in chemistry from UC Santa Barbara and a Ph.D. in chemistry from UC Davis.

Ryan Yu is a scientist in the biology group with over 10 years of research experience. Prior to joining Alumis, he was at Principia Biopharma where he developed different cellular and molecular assays to identify and validate different autoimmune disease phenotypes. Before then, he was at Five Prime Therapeutics leading antibody screens and developing 3D in vitro models to study tumor microenvironment. Ryan received his Bachelor of Science in biology from University of California, Los Angeles. He started his research career studying Alzheimer’s disease under the supervision of Harry V. Vinters, MD. He has also worked in various academic labs at UCSF and UOP School of Dentistry before starting his industry career where he investigated a wide range of biomedical topics such as stem cell regeneration, angiogenesis, and immunology.

Joyce Kwan is a Sr. Scientist in the Biology Group specializing in immunological assay development. Prior to joining Alumis, Joyce was at Principia Biopharma, where she supported multiple research programs. While there, she developed B and T cell functional assays to better- understand the complex biology of autoimmune disease targets. Joyce’s research experience spans multiple disease areas including Immuno-Oncology at Five Prime Therapeutics, Neurodegeneration at Elan Pharmaceuticals and Neuropsychiatry and Inflammation at Roche Palo Alto. Joyce earned her B.A. in Integrative Biology from U.C. Berkeley.

Mera is our Vice President in Genetics and Precision Immunology. She is an NIH/NHGRI-trained genetic epidemiologist and human geneticist. She leads Alumis’ efforts to leverage genomics and genetics to guide research and development of novel and precise therapeutics in collaboration with Foresite Labs. Mera previously did a stint in the start-up world leading the Precision Medicine and Translational Genetics group at Goldfinch Bio. Prior to Goldfinch, she spent six years at Pfizer in roles across drug discovery, development, and medical affairs. Prior to Pfizer, she was at the National Human Genome Research Institute, where she developed new methods for analyzing rare variants in DNA sequence data to discover novel genetic causes of coronary artery disease. During her early career she trained in a variety of fields, including molecular biology, bioinformatics, and science policy.

Jennifer Cortes is Sr. Executive Assistant at Alumis and brings over 20 years of executive support, event planning, and office management experience within the biopharma industry. Prior to Alumis, Jennifer directly supported the CEO, CFO and CBO of Principia Biopharma. Prior to joining Principia, Jennifer held administrative positions of increasing responsibility at Myovant Sciences, Immune Design, and Titan Pharmaceuticals primarily supporting the executive team. Jennifer received her MBA in Health Care Management and Bachelor of Science in Business / Management from University of Phoenix. She is an avid supporter of a non-profit organization (Project PEARLS) helping the poorest of the poor children to have a better life by giving them PEARLS: Peace, Education, Aspiration, Respect, Love and Smiles.

Natalie Loewenstein is a Senior Research Associate in the Biology Department at Alumis. She Joins Alumis from Principia Biopharma Inc., where she worked the last 8 years. Starting as the weekend vivarium caretaker and ending as a full-time employee and Senior Research Associate. In this role she managed all aspects of the biology lab from supply and hazardous waste sequestration and removal to performing in-vitro and in-vivo studies. Natalie received her bachelor’s degree in animal science, from UC Davis.

Josh Hoffman is our Director of Statistical Genetics at Alumis. Josh joins us from the Genomic Discovery group at Foresite Labs, where he supported incubation efforts centered around therapeutic company creation and genomics based analytical capability development. Prior to that, Josh was an investigator in the Human Genetics group at GlaxoSmithKline, where he focused on precision medicine activities spanning the use of genetics for patient stratification, repurposing clinical trial data for drug discovery, and building high-throughput variant-to-gene mapping pipelines across large scale genomic datasets. He received his Ph.D. in Human Genetics from Vanderbilt University Medical Center and completed his post-doctoral research at University of California, San Francisco.

Adrienne Robinson is Senior Director, Vendor Outsourcing and Vendor Partnerships at Alumis and brings nearly two decades of pharmaceutical and biotechnology industry experience. Adrienne joins us most recently from Kronos Bio, where she served as Director, Vendor Alliance Management, and prior to that, led the Clinical Outsourcing team at MyoKardia. Adrienne spent almost 14 years at Genentech in roles of increasing responsibility in clinical outsourcing and vendor management. She has experience with various clinical trial vendors for studies across all phases and across many indications. Adrienne holds a MBA and a Bachelor of Science in Biochemistry. She is passionate about identifying the right partners for our clinical trials and establishing and maintaining vendor relationships that ultimately result in a positive impact for our patients.

Linda Chan-Kim is the Director of Development Systems and Business Informatics at Alumis and brings more than 10 years of Informatics experience. Linda joins Alumis from Bristol Myers Squibb / MyoKardia where she was part of the Clinical Trial Business Delivery team leading the infrastructure needs for centralizing trial data in collaboration with multiple departments in support of clinical trials. Prior to joining MyoKardia, Linda held roles of increasing responsibility at Genentech Roche, providing oversight of technical vendors in support of clinical trials. Her career began in project management, developing software systems to manage clinical trials for pharmaceutical and biotech companies. Linda holds a BS in Biological Sciences from UC Davis and an MBA in Management from Golden Gate University.

Dean Dragoli is our Executive Director, Medicinal Chemistry and brings over 20 years of small molecule drug discovery to his role.  Prior to joining Alumis, Dean helped lead multiple GI and renal discovery programs to development candidate nomination at Ardelyx, utilizing tissue-targeting strategies including gut lumen restriction and pro- and soft-drug approaches.  Through his nearly ten years at Chemocentryx, Dean worked on the discovery of inhibitors for chemotactic receptors including CCR1, CCR9, and C5a, the latter of which eventually led to the approval of Tavneos^TM.  Out of graduate school, he developed library chemistries at Discovery Partners International (previously ChemRX Advanced Technologies) that would deliver from dozens to thousands of discrete lead-like small molecules and early lead op analogs for collaborators.  Dean earned his Ph.D. from the University of California, Berkeley with Jonathan Ellman in 2001, focused on developing combinatorial methodologies and asymmetric amine synthesis with tert-butanesulfinamide.